![]() ![]() The CTC subtypes (EpCAM +CK +CD45 -DAPI +CD133 + and EpCAM +CK +CD45 -DAPI +CD133 -) and CSC subtypes (CD133 +CK +CD45 -DAPI +EpCAM + and CD133 +CK +CD45 -DAPI +EpCAM -) were also analyzed using immunochemical methods. Results: The majority (84.4%) of patient blood samples were positive for CTCs (EpCAM +CK +CD45 -DAPI +) and 70.8% of patient blood samples were positive for CSCs (CD133 +CK +CD45 -DAPI +), using the highest baseline value of healthy samples as threshold. These isolated cells were further verified, via fluorescent staining and imaging, using cytokeratin (CK), CD45, and nucleic acid stain 4',6-diamidino-2-phenylindole (DAPI). Methods: From 24 patients with metastatic PDAC (stage IV, M1) undergoing active systemic treatment, we collected 78 blood samples at different time points for CTC and CSC isolation using a microfluidic platform functionalized with antibodies against a CTC biomarker, epithelial cell adhesion molecule (EpCAM), or a CSC biomarker, CD133. Liquid biopsy biomarkers, including circulating tumor cells (CTCs) and cancer stem-like cells (CSCs), hold promise for evaluating treatment response promptly and guiding therapeutic modifications. Background: Pancreatic ductal adenocarcinoma (PDAC) requires multimodal therapeutic approaches and disease monitoring for effective treatment. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |